GLUT-1 as a predictor of worse prognosis in pancreatic adenocarcinoma: immunohistochemistry study showing the correlation between expression and survival.
Mar Achalandabaso BoiraMarcello Di MartinoCarlos GordilloMagdalena AdradosElena Martín-PérezPublished in: BMC cancer (2020)
Our findings suggest that GLUT-1 could be related to higher aggressivity in PDAC and could be used as a prognostic marker, identifying patients with a worse response to current therapies who could benefit from more aggressive treatments.